MENU
+Compare
GILD
Stock ticker: NASDAQ
AS OF
Nov 19, 04:59 PM (EDT)
Price
$128.07
Change
+$0.89 (+0.70%)
Capitalization
158.89B

GILD Gilead Sciences Forecast, Technical & Fundamental Analysis

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C... Show more

Industry: #Biotechnology
GILD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
a Summary for GILD with price predictions
Nov 18, 2025

GILD's RSI Oscillator leaves overbought zone

The 10-day RSI Oscillator for GILD moved out of overbought territory on October 22, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 instances where the indicator moved out of the overbought zone. In of the 38 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 11, 2025. You may want to consider a long position or call options on GILD as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for GILD just turned positive on November 13, 2025. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in of 57 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in of 328 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.375) is normal, around the industry mean (8.823). P/E Ratio (19.825) is within average values for comparable stocks, (24.048). Projected Growth (PEG Ratio) (0.233) is also within normal values, averaging (2.059). Dividend Yield (0.024) settles around the average of (0.027) among similar stocks. P/S Ratio (5.556) is also within normal values, averaging (3.594).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
GILD
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published Earnings

GILD is expected to report earnings to fall 23.08% to $1.90 per share on February 10

Gilead Sciences GILD Stock Earnings Reports
Q4'25
Est.
$1.90
Q3'25
Beat
by $0.32
Q2'25
Beat
by $0.05
Q1'25
Beat
by $0.04
Q4'24
Beat
by $0.19
The last earnings report on October 30 showed earnings per share of $2.47, beating the estimate of $2.15. With 6.73M shares outstanding, the current market capitalization sits at 158.89B.
A.I.Advisor
published Dividends

GILD paid dividends on September 29, 2025

Gilead Sciences GILD Stock Dividends
А dividend of $0.79 per share was paid with a record date of September 29, 2025, and an ex-dividend date of September 15, 2025. Read more...
A.I. Advisor
published General Information

General Information

a developer of therapeutic products and treatments for life threatening diseases

Industry PharmaceuticalsMajor

Profile
Fundamentals
Details
Industry
Biotechnology
Address
333 Lakeside Drive
Phone
+1 650 574-3000
Employees
18000
Web
https://www.gilead.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
LABU137.601.61
+1.18%
Direxion Daily S&P Biotech Bull 3X ETF
GLDM80.570.58
+0.73%
SPDR® Gold MiniShares
DEUS56.880.14
+0.24%
Xtrackers Russell US Multifactor ETF
XRLV54.30N/A
N/A
Invesco S&P 500® ex-Rate Snsv LowVol ETF
ZAP30.09-0.01
-0.02%
Global X U.S. Electrification ETF

GILD and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with BMY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then BMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
+2.49%
BMY - GILD
49%
Loosely correlated
+0.53%
NVS - GILD
44%
Loosely correlated
-2.69%
AMGN - GILD
41%
Loosely correlated
+0.67%
GSK - GILD
41%
Loosely correlated
-0.34%
ABBV - GILD
41%
Loosely correlated
-0.06%
More